Literature DB >> 24924169

Understanding the role of Notch in osteosarcoma.

Madonna M McManus1, Kurt R Weiss, Dennis P M Hughes.   

Abstract

The Notch pathway has been described as an oncogene in osteosarcoma, but the myriad functions of all the members of this complex signaling pathway, both in malignant cells and nonmalignant components of tumors, make it more difficult to define Notch as simply an oncogene or a tumor suppressor. The cell-autonomous behaviors caused by Notch pathway manipulation may vary between cell lines but can include changes in proliferation, migration, invasiveness, oxidative stress resistance, and expression of markers associated with stemness or tumor-initiating cells. Beyond these roles, Notch signaling also plays a vital role in regulating tumor angiogenesis and vasculogenesis, which are vital aspects of osteosarcoma growth and behavior in vivo. Further, osteosarcoma cells themselves express relatively low levels of Notch ligand, making it likely that nonmalignant cells, especially endothelial cells and pericytes, are the major source of Notch activation in osteosarcoma tumors in vivo and in patients. As a result, Notch pathway expression is not expected to be uniform across a tumor but likely to be highest in those areas immediately adjacent to blood vessels. Therapeutic targeting of the Notch pathway is likewise expected to be complicated. Most pharmacologic approaches thus far have focused on inhibition of gamma secretase, a protease of the presenilin complex. This enzyme, however, has numerous other target proteins that would be expected to affect osteosarcoma behavior, including CD44, the WNT/β-catenin pathway, and Her-4. In addition, Notch plays a vital role in tissue and organ homeostasis in numerous systems, and toxicities, especially GI intolerance, have limited the effectiveness of gamma secretase inhibitors. New approaches are in development, and the downstream targets of Notch pathway signaling also may turn out to be good targets for therapy. In summary, a full understanding of the complex functions of Notch in osteosarcoma is only now unfolding, and this deeper knowledge will help position the field to better utilize novel therapies as they are developed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24924169     DOI: 10.1007/978-3-319-04843-7_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  17 in total

Review 1.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

2.  Doxorubicin activates the Notch signaling pathway in osteosarcoma.

Authors:  Hongjun Mei; Ling Yu; Peng Ji; Jian Yang; Shuo Fang; Weichun Guo; Yang Liu; Xuanyin Chen
Journal:  Oncol Lett       Date:  2015-04-21       Impact factor: 2.967

Review 3.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

4.  Silencing hsa_circRNA_0008035 exerted repressive function on osteosarcoma cell growth and migration by upregulating microRNA-375.

Authors:  Gu Gong; Zhifeng Han; Wenjun Wang; Qinli Xu; Jingzhe Zhang
Journal:  Cell Cycle       Date:  2020-08-11       Impact factor: 4.534

Review 5.  Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.

Authors:  Meera Murgai; Amber Giles; Rosandra Kaplan
Journal:  Crit Rev Oncog       Date:  2015

Review 6.  Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.

Authors:  Rocio K Rivera-Valentin; Limin Zhu; Dennis P M Hughes
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

7.  Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma.

Authors:  Zhishuang Li; Ming Jia; Xiaojuan Wu; Jingjing Cui; Aifeng Pan; Li Li
Journal:  Diagn Pathol       Date:  2015-09-17       Impact factor: 2.644

8.  Prediction of optimal gene functions for osteosarcoma using network-based- guilt by association method based on gene oncology and microarray profile.

Authors:  Xinrang Chen
Journal:  J Bone Oncol       Date:  2017-04-08       Impact factor: 4.072

Review 9.  Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma.

Authors:  Zuozhang Yang; Xiaojuan Li; Yihao Yang; Zewei He; Xin Qu; Ya Zhang
Journal:  Cell Death Dis       Date:  2016-09-29       Impact factor: 8.469

Review 10.  Novel molecular insights and new therapeutic strategies in osteosarcoma.

Authors:  Babak Otoukesh; Bahram Boddouhi; Mehdi Moghtadaei; Peyman Kaghazian; Maria Kaghazian
Journal:  Cancer Cell Int       Date:  2018-10-16       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.